Oxford Nanopore Technologies projects 2025 revenue of GBP 223–224 million, showing 24% constant-currency growth and just over GBP 300 million in cash, with ~70% of revenue from consumables and a 28% five-year CAGR. CEO Gordon Sanghera will step down, with Francis Van Parys joining in March.

At the 2026 JP Morgan Healthcare Conference, Sanghera highlighted Oxford Nanopore’s expansion in nanopore-based sequencing, with a focus on DNA, RNA, and proteomics. The company aims to enable analysis across various applications, emphasizing a low-cost genome and revenue growth from applied markets, clinical, and biopharma.

Sanghera emphasized Oxford Nanopore’s differentiation in reading native DNA and direct RNA sequencing, with a record read of 4.5 million bases. The company aims to provide a wide range of read lengths and detect modifications, targeting a $20–25 billion market opportunity with unique applications in clinical and biopharma research.

Efforts in clinical applications include infectious disease programs with faster turnaround times and significant cost savings. In biopharma, Oxford Nanopore’s workflows streamline processes, such as mRNA analytics and viral testing, delivering real-time results and saving millions for customers.

Looking ahead, the company plans to increase throughput on the PromethION platform, aiming for multiple genomes per flow cell and a low-cost genome. Sanghera discussed platform enhancements, including work on RNA, proteomics, and modifications beyond methylation, positioning Oxford Nanopore for continued growth and innovation.

CFO Nick Kehoe provided insights on the company’s financial performance, noting a shift to a traditional CAPEX model that improved cash flow and gross margin. Oxford Nanopore targets EBITDA break-even in 2027 and expects continued progress in gross margin, supported by restructuring efforts and strategic realignments.

Incoming CEO Francis Van Parys, set to join in March, brings valuable experience to Oxford Nanopore, as the company focuses on scaling up manufacturing and expanding its reach. The goal is to continue advancing nanopore-based sensing technology to enable accessible and scalable analysis of DNA, RNA, and more, benefiting society worldwide.

Read more at Yahoo Finance: Oxford Nanopore Technologies touts 24% 2025 revenue growth, CEO transition at JPM Healthcare Conference